Icosavax, Inc.: insider trades · United States · SEC (Form 4)

About Icosavax, Inc.

Icosavax, Inc. (ticker: ICVX) was a U.S.-listed biopharmaceutical company on the NASDAQ market before its acquisition was completed in February 2024. For French-speaking investors in France, Belgium, or Switzerland, the core takeaway is that Icosavax operated in healthcare, specifically in next-generation vaccines, using a proprietary protein virus-like particle (VLP) platform. The company was based in the United States, with headquarters in Seattle, Washington, and it fit the profile of a U.S. clinical-stage biotech: research-intensive, capital-hungry, and focused on value creation through pipeline advancement rather than current product sales. Founded in 2017, Icosavax was built around the goal of developing differentiated vaccines that could generate stronger immune responses than conventional approaches. Its lead asset was a combination vaccine candidate targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), aimed primarily at older adults, a population with significant unmet medical need and attractive long-term commercial potential. The company also pursued complementary respiratory disease programs, leveraging its VLP-based technology platform to create potentially broad vaccine applications. From a competitive standpoint, Icosavax was a small-cap, clinical-stage player operating in a crowded and strategically important vaccine landscape. It competed indirectly with large pharmaceutical groups, specialist vaccine developers, and other platform-based biotech companies. Because it had not yet reached commercialization, its market position depended less on revenue generation and more on clinical differentiation, manufacturing feasibility, and the ability to prove that its technology could address meaningful respiratory disease targets. That profile made the company a typical high-risk, high-upside biotech investment. The major recent event that defines the equity story is the acquisition by AstraZeneca, announced and completed in February 2024. This transaction validated the strategic value of the pipeline and the platform, and it effectively removed Icosavax as an independent listed company. As a result, any SEC Form 4 insider-transaction interest today is best viewed through an archival and transaction-history lens rather than as an ongoing standalone public equity story. In practical terms, Icosavax is best described as an innovative U.S. vaccine biotech that was listed on NASDAQ in the United States, focused on respiratory vaccines and a proprietary VLP platform, and ultimately absorbed through M&A before reaching the commercial stage. Its history highlights the typical biotech investment arc: promising science, clinical-stage optionality, strategic interest from a larger pharmaceutical acquirer, and eventual exit via takeover rather than standalone scale-up.